Polymyositis and dermatomyositis: Novel insights into the pathogenesis and potential therapeutic targets

Arash H. Lahouti, Lisa Christopher-Stine

Research output: Contribution to journalArticle

Abstract

Polymyositis (PM) and dermatomyositis (DM) are the two major forms of inflammatory muscle diseases. They are characterized clinically primarily by proximal muscle weakness. The disease mechanisms that cause muscle damage and dysfunction are not fully understood. However, because of the association with other autoimmune diseases, the presence of autoantibodies, and response to immunosuppressive medication, they are believed to be autoimmune in origin. Recent studies have highlighted the importance of the innate immune system and non-immune mechanisms and described novel adaptive immune-based pathways in the pathogenesis of polymyositis and dermatomyositis. Stimulation of Toll-like receptors (TLRs) by endogenous antigens, e.g., aminoacyl-tRNA synthetase enzyme, may trigger activation of signaling pathways and thereby induces expression of multiple genes involved in the inflammatory response. High-mobility group box-1 (HMGB1) might interact with the same receptors and cause skeletal muscle inflammation. In addition, this protein may be involved in T lymphocyte survival in muscle tissue. A newly described T cell subset, CD28-T cells, may have strong myotoxic properties and comprises the predominant muscle-infiltrating T cell phenotype. Future studies should focus more on understanding the relative contribution of each pathway to the pathogenesis of inflammatory myopathies. Given the connections between the pathways, targeting multiple pathways through combination therapies may be beneficial.

Original languageEnglish (US)
Pages (from-to)463-470
Number of pages8
JournalDiscovery medicine
Volume19
Issue number107
StatePublished - 2015

Fingerprint

Dermatomyositis
Myositis
T-Lymphocytes
Muscles
Amino Acyl-tRNA Synthetases
Toll-Like Receptors
Muscle Weakness
T-Lymphocyte Subsets
Immunosuppressive Agents
Autoantibodies
Autoimmune Diseases
Immune System
Skeletal Muscle
Therapeutics
Inflammation
Phenotype
Gene Expression
Antigens
Enzymes
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Polymyositis and dermatomyositis : Novel insights into the pathogenesis and potential therapeutic targets. / Lahouti, Arash H.; Christopher-Stine, Lisa.

In: Discovery medicine, Vol. 19, No. 107, 2015, p. 463-470.

Research output: Contribution to journalArticle

@article{8f9f65d0b39a4c42a40f14061a808836,
title = "Polymyositis and dermatomyositis: Novel insights into the pathogenesis and potential therapeutic targets",
abstract = "Polymyositis (PM) and dermatomyositis (DM) are the two major forms of inflammatory muscle diseases. They are characterized clinically primarily by proximal muscle weakness. The disease mechanisms that cause muscle damage and dysfunction are not fully understood. However, because of the association with other autoimmune diseases, the presence of autoantibodies, and response to immunosuppressive medication, they are believed to be autoimmune in origin. Recent studies have highlighted the importance of the innate immune system and non-immune mechanisms and described novel adaptive immune-based pathways in the pathogenesis of polymyositis and dermatomyositis. Stimulation of Toll-like receptors (TLRs) by endogenous antigens, e.g., aminoacyl-tRNA synthetase enzyme, may trigger activation of signaling pathways and thereby induces expression of multiple genes involved in the inflammatory response. High-mobility group box-1 (HMGB1) might interact with the same receptors and cause skeletal muscle inflammation. In addition, this protein may be involved in T lymphocyte survival in muscle tissue. A newly described T cell subset, CD28-T cells, may have strong myotoxic properties and comprises the predominant muscle-infiltrating T cell phenotype. Future studies should focus more on understanding the relative contribution of each pathway to the pathogenesis of inflammatory myopathies. Given the connections between the pathways, targeting multiple pathways through combination therapies may be beneficial.",
author = "Lahouti, {Arash H.} and Lisa Christopher-Stine",
year = "2015",
language = "English (US)",
volume = "19",
pages = "463--470",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "107",

}

TY - JOUR

T1 - Polymyositis and dermatomyositis

T2 - Novel insights into the pathogenesis and potential therapeutic targets

AU - Lahouti, Arash H.

AU - Christopher-Stine, Lisa

PY - 2015

Y1 - 2015

N2 - Polymyositis (PM) and dermatomyositis (DM) are the two major forms of inflammatory muscle diseases. They are characterized clinically primarily by proximal muscle weakness. The disease mechanisms that cause muscle damage and dysfunction are not fully understood. However, because of the association with other autoimmune diseases, the presence of autoantibodies, and response to immunosuppressive medication, they are believed to be autoimmune in origin. Recent studies have highlighted the importance of the innate immune system and non-immune mechanisms and described novel adaptive immune-based pathways in the pathogenesis of polymyositis and dermatomyositis. Stimulation of Toll-like receptors (TLRs) by endogenous antigens, e.g., aminoacyl-tRNA synthetase enzyme, may trigger activation of signaling pathways and thereby induces expression of multiple genes involved in the inflammatory response. High-mobility group box-1 (HMGB1) might interact with the same receptors and cause skeletal muscle inflammation. In addition, this protein may be involved in T lymphocyte survival in muscle tissue. A newly described T cell subset, CD28-T cells, may have strong myotoxic properties and comprises the predominant muscle-infiltrating T cell phenotype. Future studies should focus more on understanding the relative contribution of each pathway to the pathogenesis of inflammatory myopathies. Given the connections between the pathways, targeting multiple pathways through combination therapies may be beneficial.

AB - Polymyositis (PM) and dermatomyositis (DM) are the two major forms of inflammatory muscle diseases. They are characterized clinically primarily by proximal muscle weakness. The disease mechanisms that cause muscle damage and dysfunction are not fully understood. However, because of the association with other autoimmune diseases, the presence of autoantibodies, and response to immunosuppressive medication, they are believed to be autoimmune in origin. Recent studies have highlighted the importance of the innate immune system and non-immune mechanisms and described novel adaptive immune-based pathways in the pathogenesis of polymyositis and dermatomyositis. Stimulation of Toll-like receptors (TLRs) by endogenous antigens, e.g., aminoacyl-tRNA synthetase enzyme, may trigger activation of signaling pathways and thereby induces expression of multiple genes involved in the inflammatory response. High-mobility group box-1 (HMGB1) might interact with the same receptors and cause skeletal muscle inflammation. In addition, this protein may be involved in T lymphocyte survival in muscle tissue. A newly described T cell subset, CD28-T cells, may have strong myotoxic properties and comprises the predominant muscle-infiltrating T cell phenotype. Future studies should focus more on understanding the relative contribution of each pathway to the pathogenesis of inflammatory myopathies. Given the connections between the pathways, targeting multiple pathways through combination therapies may be beneficial.

UR - http://www.scopus.com/inward/record.url?scp=84940474099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940474099&partnerID=8YFLogxK

M3 - Article

C2 - 26175404

AN - SCOPUS:84940474099

VL - 19

SP - 463

EP - 470

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 107

ER -